Renalytix Plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more
Market Cap & Net Worth: Renalytix Plc (RNLXY)
Renalytix Plc (OTCQB:RNLXY) has a market capitalization of $50.26 Million ($50.26 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #19092 globally and #7040 in its home market, demonstrating a -9.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Renalytix Plc's stock price $0.23 by its total outstanding shares 218509340 (218.51 Million).
Renalytix Plc Market Cap History: 2024 to 2025
Renalytix Plc's market capitalization history from 2024 to 2025. Data shows growth from $31.73 Million to $50.26 Million (0.00% CAGR).
Renalytix Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Renalytix Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
16.75x
Renalytix Plc's market cap is 16.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $31.73 Million | $2.30 Million | -$45.50 Million | 13.79x | N/A |
| 2025 | $50.26 Million | $3.00 Million | -$20.40 Million | 16.75x | N/A |
Competitor Companies of RNLXY by Market Capitalization
Companies near Renalytix Plc in the global market cap rankings as of March 18, 2026.
Key companies related to Renalytix Plc by market ranking:
- Genovis AB (publ.) (ST:GENO): Ranked #19083 globally with a market cap of $81.58 Million USD ( Skr915.14 Million SEK).
- Salim Ivomas Pratama Tbk (JK:SIMP): Ranked #19084 globally with a market cap of $81.57 Million USD ( Rp1.33 Trillion IDR).
- GENOR BIOPHARMA DL-00002 (F:67N0): Ranked #19093 globally with a market cap of $81.40 Million USD ( €79.30 Million EUR).
- OPTGF (PINK:OPTGF): Ranked #19094 globally with a market cap of $81.36 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #19083 | Genovis AB (publ.) | ST:GENO | $81.58 Million | Skr16.20 |
| #19084 | Salim Ivomas Pratama Tbk | JK:SIMP | $81.57 Million | Rp590.00 |
| #19093 | GENOR BIOPHARMA DL-00002 | F:67N0 | $81.40 Million | €0.29 |
| #19094 | OPTGF | PINK:OPTGF | $81.36 Million | $2.62 |
Renalytix Plc Historical Marketcap From 2024 to 2025
Between 2024 and today, Renalytix Plc's market cap moved from $31.73 Million to $ 50.26 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $50.26 Million | +58.40% |
| 2024 | $31.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Renalytix Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.26 Million USD |
| MoneyControl | $50.26 Million USD |
| MarketWatch | $50.26 Million USD |
| marketcap.company | $50.26 Million USD |
| Reuters | $50.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.